Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')

作者
Luca Gianni,Tadeusz Pieńkowski,Y-H Im,L Roman,L-M Tseng,M-C Liu,A. Lluch-Hernández,Владимир Федорович Семиглазов,Tania Szado,G. A. Ross
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:70 (24_Supplement): S3-2 被引量:67
标识
DOI:10.1158/0008-5472.sabcs10-s3-2
摘要

Abstract Background: P binds to HER2 and has complementary mechanisms of action with H. A clinical study of P+H showed meaningful activity in patients (pts) with metastatic HER2-positive breast cancer whose disease progressed on prior H therapy (Baselga et al. JCO 2010). NeoSphere is a Phase II randomized trial of preoperative systemic therapy comparing H and docetaxel (TH), THP, HP and TP to rank antitumor activity and tolerability. Methods: 417 pts with centrally-confirmed HER2-positive (IHC 3+ or FISH positive) breast cancer (stage II or III including locally advanced) were randomized to receive 4 cycles of TH (n=107), THP (n=107), HP (n=107), or TP (n=96) before surgery. Cycles were given intravenously q3w: P, 840 mg loading dose and 420 mg maintenance; H 8 mg/kg loading dose and 6 mg/kg maintenance; T, 75 mg/m2 with escalation to 100 mg/m2 if the starting dose was well tolerated. After surgery all pts received H to 1 year and 3 cycles of FEC; in case of neoadjuvant HP they also received T before FEC. The primary endpoint was rate of pathological complete response (pCR) in the breast. For all patients, a tissue sample at baseline, as well as at surgery following 4 cycles of neoadjuvant therapy, was collected for biomarker analyses. Results: Baseline characteristics were well balanced. About 40% of patients had locally advanced/inflammatory breast cancer. In the intent-to-treat analysis the rates of pCR and clinical objective response in the breast were: pCR for THP was significantly higher (p=0.014) than TH which was significantly higher than HP (p=0.031). Clinical disease progression was reported in 1 patient on TH and 2 patients on HP. Feasibility was good for all T-containing arms. Adverse events of grade ≥3 were rare (<7%) with HP in sharp contrast with the >50% incidence in T-containing arms. One pt developed congestive heart failure with HP. Five more patients had asymptomatic decreased LVEF with TH (1), THP (3) and TP (1) that resolved at the subsequent assessment. Biomarker analysis is ongoing. Conclusions: These data show the superior antitumor activity of THP and very favorable therapeutic ratio for HP that justify continuing study of the two monoclonals with and without docetaxel in women with HER2- positive early or metastatic breast cancer. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr S3-2.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
AllRightReserved完成签到 ,获得积分0
1秒前
无限凛发布了新的文献求助10
1秒前
搞怪建辉发布了新的文献求助30
1秒前
大个的应助被哒哒哒采纳,获得10
1秒前
1秒前
1秒前
1秒前
2秒前
发文章完成签到,获得积分10
2秒前
可爱的函函的应助被派大星采纳,获得10
2秒前
超级鸭子完成签到,获得积分10
3秒前
111完成签到,获得积分10
3秒前
汉堡包的应助被想飞的猪采纳,获得10
4秒前
5秒前
5秒前
5秒前
5秒前
5秒前
5秒前
5秒前
5秒前
5秒前
111发布了新的文献求助10
5秒前
5秒前
5秒前
zzmyyds完成签到 ,获得积分10
6秒前
hc发布了新的文献求助10
6秒前
6秒前
小明同学发布了新的文献求助10
6秒前
dandan发布了新的文献求助10
7秒前
bkagyin的应助被哒哒哒采纳,获得10
7秒前
星月发布了新的文献求助10
8秒前
养颜发布了新的文献求助10
8秒前
8秒前
9秒前
英俊的铭的应助被科研通管家采纳,获得10
9秒前
零负一的应助被科研通管家采纳,获得10
9秒前
9秒前
今后的应助被科研通管家采纳,获得10
9秒前
汉堡包的应助被科研通管家采纳,获得10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163922
求助须知:如何正确求助?哪些是违规求助? 9557995
关于积分的说明 21743022
捐赠科研通 7754548
什么是DOI,文献DOI怎么找? 3428401
关于科研通互助平台的介绍 2553053
邀请新用户注册赠送积分活动 2473008